BioNTech plans to bring artificial intelligence deeper into its biotechnology research by acquiring InstaDeep, its UK collaboration partner. The deal is intended to strengthen the company’s technology capabilities and support work on drug discovery, immunotherapies and vaccines.
From collaboration to acquisition
BioNTech is acquiring 100 percent of InstaDeep for up to 562 million British pounds. The company will pay 362 million British pounds upfront in a mix of cash and shares, with another 200 million British pounds potentially paid through performance-based milestone payments.
The acquisition was expected to be completed in the first half of 2023. BioNTech is particularly known for its Covid vaccine, but the stated aim of the deal extends across its research and technology work.
The companies had been collaborating since 2019. In November 2020, they announced a multi-year strategic collaboration and the creation of a joint AI Innovation Lab. The acquisition would bring that partnership inside BioNTech and expand the capabilities available to its teams.
Building AI into biotechnology research
The deal is expected to add 240 highly skilled professionals to BioNTech, including teams working in AI, ML, bioengineering, data science and software development. That mix connects computational expertise with the biological and engineering work needed to develop medicines.
BioNTech CEO and Co-founder Uğur Şahin said the company’s focus since its founding had included computational solutions for personalized immunotherapies. He said the acquisition would let BioNTech integrate “the rapidly evolving AI capabilities” into its technologies, research, drug discovery, manufacturing and deployment processes.
InstaDeep CEO and co-founder Karim Beguir described a shared vision of combining biopharmaceutical research and artificial intelligence to create next-generation immunotherapies. The stated ambition is to help fight cancer and other diseases with high unmet medical needs.
Designing and testing candidates at scale
BioNTech plans to integrate InstaDeep’s AI models into its research platforms and connect them to an integrated automated laboratory infrastructure. The intended result is high-throughput design and testing of novel drug candidates at scale.
In practical terms, this plan links computational systems with laboratory work: AI models are to be incorporated into research platforms, while automated infrastructure supports candidate testing. The article describes a goal for how these capabilities could work together, rather than reporting that the approach has already produced new drugs.
BioNTech also plans to develop additional AI solutions and deploy them in key strategic and operational functions. That broadens the role described for AI beyond drug discovery alone, extending it to other parts of the company’s work.
A wider push to apply AI in medicine
The article presents AI as a foundational technology with potential to accelerate other sciences. It points to Deepmind’s Alphafold for protein folding prediction as an example: the system outperforms existing methods and thereby accelerates medical research.
BioNTech is entering a field with prominent competition. Deepmind and its parent company Alphabet formed Isomorphic Labs in 2021 to bring AI to medical practice. The acquisition of InstaDeep positions BioNTech to build its own combination of biopharmaceutical research and artificial intelligence.
The deal’s central promise is to connect AI expertise, research platforms and automated laboratory work within one company. Whether those plans translate into faster drug development will depend on how the capabilities are integrated and used; the source describes the intended direction, not a measured outcome.